Published in Gut on May 01, 1988
Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ (1992) 1.94
Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm (2015) 0.89
Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J (1974) 2.24
Sensitivity to azathioprine. Med J Aust (1972) 1.84
Hypersensitivity and jaundice due to azathioprine. Postgrad Med J (1980) 1.81
Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) (1982) 1.75
Azathioprine-induced shock. Br Med J (Clin Res Ed) (1981) 1.22
Adverse effects of azathioprine. Adverse Drug React Acute Poisoning Rev (1984) 0.98
Life-threatening hypotension associated with azathioprine therapy. A case report. S Afr Med J (1984) 0.92
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.89
Risk assessment after acute upper gastrointestinal haemorrhage. Gut (1996) 5.02
Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage. National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet (1996) 4.55
Policy alternatives for resource allocation. Lancet (1977) 4.52
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med (1998) 3.96
Recommendations for standards of sedation and patient monitoring during gastrointestinal endoscopy. Gut (1991) 3.27
Effect of reactive pharmacy intervention on quality of hospital prescribing. BMJ (1990) 3.25
Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut (1984) 3.18
Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ (1992) 3.17
Sedation for upper gastrointestinal endoscopy: results of a nationwide survey. Gut (1991) 3.14
Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology (1985) 3.12
Changes in clinical features of coeliac disease in adults in Edinburgh and the Lothians 1960-79. Br Med J (Clin Res Ed) (1983) 2.91
Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy (2007) 2.88
14C-urea breath analysis, a non-invasive test for Campylobacter pylori in the stomach. Lancet (1987) 2.68
Prevention of hypoxaemia during upper-gastrointestinal endoscopy by means of oxygen via nasal cannulae. Lancet (1987) 2.60
Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet (2001) 2.44
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med (1996) 2.37
Intravenous midazolam: a study of the degree of oxygen desaturation occurring during upper gastrointestinal endoscopy. Br J Clin Pharmacol (1987) 2.36
What is value for money in medical care? Experiences in England and Wales, Sweden, and the U. S. A. Lancet (1967) 2.36
Prevalence and "incidence" of celiac disease in Edinburgh and the Lothian region of Scotland. Gastroenterology (1986) 2.34
Effect of daily oral omeprazole on 24 hour intragastric acidity. Br Med J (Clin Res Ed) (1983) 2.30
A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer (2000) 2.27
Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet (1993) 2.20
Smoking and Crohn's disease. Br Med J (Clin Res Ed) (1984) 2.17
Hospital caseloads in Liverpool, New England, and Uppsala. An international comparison. Lancet (1968) 2.12
Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A (1997) 2.12
Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med (1983) 2.10
Audit of outcome of long-term enteral nutrition by percutaneous endoscopic gastrostomy. Lancet (1993) 2.10
Smoking and ulcerative colitis. Br Med J (Clin Res Ed) (1984) 2.05
Cigarette smoking and inflammatory bowel disease. Gastroenterology (1987) 2.04
Variation in outcome after acute upper gastrointestinal haemorrhage. The National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet (1995) 2.03
Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study. Gut (1998) 2.02
Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ (1994) 1.99
Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ (1992) 1.94
Prescribing in the UK. Lancet (2001) 1.93
Journals should see original protocols for clinical trials. BMJ (2001) 1.88
Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet (1983) 1.88
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 1.87
Pharmacokinetics of ketoconazole in normal subjects. J Antimicrob Chemother (1981) 1.84
Physiological and pharmacological variability in estimated hepatic blood flow in man. Br J Clin Pharmacol (1981) 1.81
Reduction of gastrointestinal protein loss by elemental diet in Crohn's disease of the small bowel. Gut (1981) 1.77
Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs (1998) 1.74
Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2. Am J Physiol (1997) 1.70
Primary biliary cirrhosis and coeliac disease: an association? Lancet (1978) 1.70
Simple and accurate PCR-based system for typing vacuolating cytotoxin alleles of Helicobacter pylori. J Clin Microbiol (1999) 1.69
Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut (2000) 1.69
Audit of mortality in upper gastrointestinal bleeding. Postgrad Med J (1989) 1.68
What predicts failed cannulation and therapy at ERCP? Results of a large-scale multicenter analysis. Endoscopy (2012) 1.68
Risks, costs, and compliance limit colorectal adenoma surveillance: lessons from a randomised trial. Gut (2001) 1.63
Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J (Clin Res Ed) (1984) 1.61
Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis. Gut (1982) 1.59
Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology (1997) 1.59
High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut (1991) 1.58
Vitamin A treatment for night blindness in primary biliary cirrhosis. Br Med J (Clin Res Ed) (1984) 1.57
Carotinaemia. Br Med J (1942) 1.55
Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis. Clin Sci (Lond) (1992) 1.53
Comparison of twice-daily ranitidine with standard cimetidine treatment of duodenal ulcer. Gut (1981) 1.50
The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects. Br J Clin Pharmacol (1982) 1.49
Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther (2010) 1.48
Paying for medical care. Need for debate. Lancet (1970) 1.48
Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett's esophagus: a meta-analysis. Endoscopy (2010) 1.44
Death in acute upper gastrointestinal bleeding. Can endoscopy reduce mortality? Lancet (1976) 1.43
Normal human colonic subepithelial myofibroblasts enhance epithelial migration (restitution) via TGF-beta3. Am J Physiol (1999) 1.42
Effects of oral pantoprazole on 24-hour intragastric acidity and plasma gastrin profiles. Aliment Pharmacol Ther (1992) 1.40
The Medical Check-up or Pre-symptomatic Diagnosis [Abridged]. Proc R Soc Med (1963) 1.40
Ileo-caecal ulceration associated with the use of diclofenac slow release. Aliment Pharmacol Ther (1993) 1.40
Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess (2010) 1.40
Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther (2005) 1.40
Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer. Gut (1988) 1.40
Filgrastim for mesalazine-associated neutropenia. Lancet (1993) 1.39
Monoclonal antigranulocyte antibody imaging in inflammatory bowel disease: a preliminary report. Nucl Med Commun (1992) 1.39
Mortality study of 18 000 patients treated with omeprazole. Gut (2003) 1.39
Day-to-day variation of 24-hour intragastric acidity. Gastroenterology (1988) 1.39
Somatostatin in treatment of haematemesis and melaena. Lancet (1985) 1.39
The Prader-Willi syndrome with a 15/15 translocation. Case report and review of the literature. J Med Genet (1976) 1.38
Biosynthesis of lipoxygenase and cyclo-oxygenase products from [14C]-arachidonic acid by human colonic mucosa. Gut (1983) 1.37
Prostaglandins and ulcerative colitis. Gut (1984) 1.36
Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther (2002) 1.35
Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. J Antimicrob Chemother (1983) 1.34
An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol (2003) 1.34
Oesophageal cancer: a population-based study of survival after treatment. Br J Surg (1992) 1.33
Rising death rate from non-malignant disease of the oesophagus (NMOD) in England and Wales. Gut (1995) 1.32
Screening for gastric cancer after gastric surgery. Lancet (1983) 1.32
Inhibition of prostaglandin synthetase in human rectal mucosa. Gut (1983) 1.32
Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther (2005) 1.32
Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother (1984) 1.31
Intravenous omeprazole rapidly raises intragastric pH. Gut (1985) 1.31
High definition colonoscopy vs. standard video endoscopy for the detection of colonic polyps: a meta-analysis. Endoscopy (2011) 1.30